Turning the Tide on a Deadly Cancer: What Every Clinician Needs to Know About Lung Cancer Screening

Presentation

Session Details

This Grand Rounds session will cover critical updates in the screening of lung cancer. This includes the latest advancements in screening eligibility, quality screening and diagnostic algorithms, and workflow resources to build into practice. The session will provide an overview of the epidemiology of lung cancer in the state and current trends in screening uptake. Case studies will offer practical examples of how to implement lung cancer screening into routine care. Subject matter experts will equip health care professionals with the latest knowledge and tools to enhance their practice in the early detection of one of the most common causes of cancer deaths across New York State.

Moderator:

James V. McDonald, MD, MPH
Commissioner of the New York State Department of Health

Presenters:

Dr. Heather Dacus is a board-certified preventive medicine physician who joined the New York State Department of Health in 2007. She serves as director of the Bureau of Cancer Prevention and Control.

Dr. Fortuna is a professor of Internal Medicine, Pediatrics and Community Health at the University of Rochester (UR). He is a practicing internist, pediatrician, and health services researcher. Dr. Fortuna received his medical degree from Dartmouth Medical School and his Master of Public Health (MPH) from the Harvard School of Public Health. He completed residency training in Internal Medicine and Pediatrics at Brigham and Women's Hospital, MGH, and Boston Children's Hospital. He subsequently completed a general medicine fellowship at the Department of Population Medicine, Harvard Medical School.

Dr. Fortuna is the medical director for Quality and Population Health in the UR Primary Care Network, which includes 42 primary care practices across Upstate NY and provides care to over 261,000 patients.

Special Guest:

Dr. Qaqish is a thoracic surgeon at Erie County Medical Center and clinical assistant professor at the University at Buffalo in Buffalo, New York. He is a diplomate of the American Board of Surgery and the American Board of Thoracic Surgery. His practice focus is on lung cancer screening, diagnosis, staging, and treatment of lung cancer using minimally invasive robotic-assisted surgery.

Continuing Medical Education

To Obtain CME Credits:

Participants seeking CME credits must register with their email, attend the entire live session, and complete an evaluation and posttest available at the end of the session.

Accreditation Statement:

This activity is planned and implemented in accordance with the ACCME's Accreditation Requirements and Policies through the joint providership of the Medical Society of the State of New York (MSSNY) and The New York State Department of Health. MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

MSSNY designates this Grand Rounds session for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with their participation.

Disclosure Statement:

As an ACCME-accredited provider, MSSNY is required to identify and mitigate relevant financial relationships of all individuals in control of CME content. Relevant financial relationships exist if:

  • A financial relationship, in any amount, exists between the content controller and an ineligible company.
  • The financial relationship existed in the past 24 months.
  • The content of the education is related to the products of an ineligible company with whom the person has a financial relationship.

**John Maese, MD, has disclosed that he owns stock in Eli Lilly and Company, Johnson & Johnson, Danaher Corporation, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc. The planners, moderator, presenters, and other individuals in control of content do not have any financial arrangements or affiliations with any ineligible companies whose products, research, or services may be discussed in this activity. All relevant financial relationships have been mitigated.

**No commercial funding has been accepted for this activity.